A nasal spray to prevent Covid-19 infection developed by Thai medical researchers will be available for commercial sale from Oct 1, Worawan Chaikamnerd, chief executive officer of Hibiocy Co and Rojukiss International Public Company Ltd announced on Monday.
Ms Worawan said it would be sold under the brandname "VAILL COVITRAP Anti-Cov Nasal Spray" and was produced by Hibiocy Co, a subsidiary of Rojukiss International.
Developed by a team of doctors and researchers from the faculty of medicine, Chulalongkorn University, the spray is truly a Thai innovation for Thai people, she said.
The spray is designed to coat the nasal cavities with HPMC to reduce the amount of the virus and prevent it from entering the body through the holes of the nose. It can be applied every six hours, or three times a day.
VAILL COVITRAP Anti-Cov Nasal Spray will be available for commercial sale from Oct 1. More information can be obtained from official Line@Covitrap and Facebook as well as from pharmacists at the Government Pharmaceutical Organisation's drugstores and medical clinics - The Senizens and Panacura, she said.
Dr Nopporn Chuenklin, director of the Health Systems Research Institute (HSRI), was full of praise for the product, saying it is an outstanding Thai innovation for which patent rights have been registered.
It had been passed on to the private sector for production and distribution, he said.
